SG10202007176TA - Anti-cd47 antibodies and uses thereof - Google Patents

Anti-cd47 antibodies and uses thereof

Info

Publication number
SG10202007176TA
SG10202007176TA SG10202007176TA SG10202007176TA SG10202007176TA SG 10202007176T A SG10202007176T A SG 10202007176TA SG 10202007176T A SG10202007176T A SG 10202007176TA SG 10202007176T A SG10202007176T A SG 10202007176TA SG 10202007176T A SG10202007176T A SG 10202007176TA
Authority
SG
Singapore
Prior art keywords
antibodies
Prior art date
Application number
SG10202007176TA
Other languages
English (en)
Inventor
Aaron Sato
Ryan Stafford
Junhao Yang
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of SG10202007176TA publication Critical patent/SG10202007176TA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
SG10202007176TA 2014-12-30 2015-12-28 Anti-cd47 antibodies and uses thereof SG10202007176TA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462098291P 2014-12-30 2014-12-30

Publications (1)

Publication Number Publication Date
SG10202007176TA true SG10202007176TA (en) 2020-08-28

Family

ID=56284963

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10202007176TA SG10202007176TA (en) 2014-12-30 2015-12-28 Anti-cd47 antibodies and uses thereof
SG11201705310TA SG11201705310TA (en) 2014-12-30 2015-12-28 Anti-cd47 antibodies and uses thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11201705310TA SG11201705310TA (en) 2014-12-30 2015-12-28 Anti-cd47 antibodies and uses thereof

Country Status (17)

Country Link
US (2) US10870699B2 (ru)
EP (1) EP3240569A4 (ru)
JP (2) JP6850255B2 (ru)
KR (1) KR102489471B1 (ru)
CN (1) CN107530421B (ru)
AU (1) AU2015374301B2 (ru)
BR (1) BR112017014258A2 (ru)
CA (1) CA2972604C (ru)
CL (1) CL2017001736A1 (ru)
CO (1) CO2017007673A2 (ru)
EA (1) EA037654B1 (ru)
EC (1) ECSP17041865A (ru)
HK (1) HK1245154A1 (ru)
MX (1) MX2017008819A (ru)
SG (2) SG10202007176TA (ru)
WO (1) WO2016109415A1 (ru)
ZA (1) ZA201704467B (ru)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10870699B2 (en) 2014-12-30 2020-12-22 Celgene Corporation Anti-CD47 antibodies and uses thereof
CN114316067A (zh) * 2015-05-04 2022-04-12 皮里斯制药有限公司 抗癌融合多肽
KR20190035737A (ko) * 2016-07-06 2019-04-03 셀진 코포레이션 낮은 면역원성을 갖는 항체 및 이의 용도
IL265605B1 (en) 2016-09-29 2024-02-01 Beijing Hanmi Pharmaceutical Co Ltd Heterodimeric immunoglobulin structures, a pharmaceutical preparation containing them, their use and methods for their preparation
BR112019008010A2 (pt) 2016-10-20 2019-07-09 I Mab anticorpo monoclonal isolado ou fragmento imunologicamente ativo do mesmo, anticorpo monoclonal biespecífico isolado, composição farmacêutica, método para tratamento de uma doença em um sujeito humano em necessidade do mesmo, proteína de fusão, epítopo imunodominante codificado pelo gene cd47, e, molécula biológica
WO2018081898A1 (en) 2016-11-03 2018-05-11 Trillium Therapeutics Inc. Improvements in cd47 blockade therapy by hdac inhibitors
EP3538557A4 (en) * 2016-11-08 2020-11-18 Ablexis, LLC ANTI-CD47 ANTIBODIES
CN109963876B (zh) 2016-11-18 2023-11-14 北京韩美药品有限公司 抗pd-1/抗her2天然抗体结构样异源二聚体形式双特异抗体及其制备
US11267885B2 (en) 2017-01-26 2022-03-08 Zlip Holding Limited CD47 antigen binding unit and uses thereof
CN110300603B (zh) * 2017-02-14 2023-04-14 亘喜生物科技（上海）有限公司 Cd47-car-t细胞
WO2018183182A1 (en) * 2017-03-27 2018-10-04 Celgene Corporation Methods and compositions for reduction of immunogenicity
EP3610022A1 (en) 2017-04-14 2020-02-19 Tollnine, Inc. Immunomodulating polynucleotides, antibody conjugates thereof, and methods of their use
NZ761568A (en) * 2017-08-02 2022-11-25 Phanes Therapeutics Inc Anti-cd47 antibodies and uses thereof
WO2019034895A1 (en) * 2017-08-18 2019-02-21 Ultrahuman Four Limited LIAISON AGENTS
KR20220028157A (ko) * 2017-11-10 2022-03-08 아이-맵 바이오파마 유에스 리미티드 Cd47 항체 및 사이토카인을 포함하는 융합 단백질
KR20200091901A (ko) 2017-12-01 2020-07-31 시애틀 지네틱스, 인크. 암을 치료하기 위한 cd47 항체 및 이의 용도
JP7231641B2 (ja) 2017-12-04 2023-03-01 北京韓美薬品有限公司 天然抗体様構造を有し、ヘテロ二量体形態の抗ｐｄ－ｌ１／抗ｃｄ４７二重特異性抗体、ならびにその製造方法
TW201932493A (zh) * 2018-01-24 2019-08-16 大陸商南京傳奇生物科技有限公司 不致顯著紅血球凝集的抗－ｃｄ４７抗體
WO2019153200A1 (zh) 2018-02-08 2019-08-15 北京韩美药品有限公司 抗pd-1/抗her2天然抗体结构样异源二聚体形式双特异抗体及其制备
GB201804860D0 (en) * 2018-03-27 2018-05-09 Ultrahuman Two Ltd CD47 Binding agents
CN110577597B (zh) * 2018-06-11 2021-10-22 康诺亚生物医药科技（成都）有限公司 一种阻断CD47和SIRPα相互作用的抗体
US11634490B2 (en) 2018-06-15 2023-04-25 Accurus Biosciences, Inc. Blocking antibodies against CD47 and methods of use thereof
EP3817769A4 (en) * 2018-07-05 2022-03-30 Trican Biotechnology Co., Ltd HUMAN ANTI-CD47 ANTIBODIES AND THEIR USES
CN110872348B (zh) * 2018-09-03 2021-09-03 长春金赛药业有限责任公司 人源化抗cd47单克隆抗体及其应用
MX2021004779A (es) * 2018-10-31 2021-06-08 I Mab Biopharma Us Ltd Anticuerpos cd47 novedosos y metodos para usarlos.
CA3132078A1 (en) * 2019-03-06 2020-09-10 Jiangsu Hengrui Medicine Co., Ltd. Bifunctional fusion protein and pharmaceutical use thereof
TW202045550A (zh) 2019-04-05 2020-12-16 美商西建公司 腫瘤選擇性結合cd47之抗體之工程
MA56119A (fr) 2019-06-07 2022-04-13 Alx Oncology Inc Procédés et réactifs pour réduire les interférences de médicaments se liant au cd47 dans des dosages sérologiques
CA3145791A1 (en) 2019-07-16 2021-01-21 Gilead Sciences, Inc. Hiv vaccines and methods of making and using
PL4045083T3 (pl) 2019-10-18 2024-05-13 Forty Seven, Inc. Terapie skojarzone do leczenia zespołów mielodysplastycznych i ostrej białaczki szpikowej
WO2021078219A1 (en) * 2019-10-25 2021-04-29 Wuxi Biologics (Shanghai) Co., Ltd. Novel anti-cd47 antibodies and uses thereof
MX2022005123A (es) 2019-10-31 2022-05-30 Forty Seven Inc Tratamiento basado en anti-cd47 y anti-cd20 para cancer hematologico.
AU2020412875A1 (en) 2019-12-24 2022-06-23 Carna Biosciences, Inc. Diacylglycerol kinase modulating compounds
AU2021219668A1 (en) 2020-02-14 2022-08-25 Gilead Sciences, Inc. Antibodies and fusion proteins that bind to CCR8 and uses thereof
US11920136B2 (en) 2020-02-28 2024-03-05 Tallac Therapeutics, Inc. Transglutaminase-mediated conjugation
WO2021262765A1 (en) 2020-06-22 2021-12-30 The Board Of Trustees Of The Leland Stanford Junior University Tsp-1 inhibitors for the treatment of aged, atrophied or dystrophied muscle
IL301292A (en) * 2020-09-14 2023-05-01 Sutro Biopharma Inc A method for the large-scale production of antibodies using a cell-free protein synthesis system
US20230365681A1 (en) 2020-10-07 2023-11-16 Celgene Corporation Bispecific antibody treatment of lymphoid malignant neoplasm conditions
WO2022120286A1 (en) 2020-12-06 2022-06-09 ALX Oncology Inc. Multimers for reducing the interference of drugs that bind cd47 in serological assays
CN114656566B (zh) * 2020-12-23 2023-09-22 广东菲鹏制药股份有限公司 一种靶向cd47的抗体及其应用
EP4276113A1 (en) 2021-01-08 2023-11-15 Beijing Hanmi Pharmaceutical Co., Ltd. Antibody specifically binding to cd47 and antigen-binding fragment thereof
WO2022190058A1 (en) 2021-03-12 2022-09-15 Dcprime B.V. Methods of vaccination and use of cd47 blockade
TW202302145A (zh) 2021-04-14 2023-01-16 美商基利科學股份有限公司 ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症
US20220389104A1 (en) * 2021-05-28 2022-12-08 Ose Immunotherapeutics Method for Treating CD127-Positive Cancers by Administering an Anti-CD127 Agent
EP4359389A1 (en) 2021-06-23 2024-05-01 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
CN117355531A (zh) 2021-06-23 2024-01-05 吉利德科学公司 二酰基甘油激酶调节化合物
EP4359411A1 (en) 2021-06-23 2024-05-01 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
CN117396478A (zh) 2021-06-23 2024-01-12 吉利德科学公司 二酰基甘油激酶调节化合物
TW202330504A (zh) 2021-10-28 2023-08-01 美商基利科學股份有限公司 嗒𠯤—３（２ｈ）—酮衍生物
WO2023077030A1 (en) 2021-10-29 2023-05-04 Gilead Sciences, Inc. Cd73 compounds
WO2023122581A2 (en) 2021-12-22 2023-06-29 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
US20230242508A1 (en) 2021-12-22 2023-08-03 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
TW202340168A (zh) 2022-01-28 2023-10-16 美商基利科學股份有限公司 Ｐａｒｐ７抑制劑
US20230373950A1 (en) 2022-03-17 2023-11-23 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
WO2023183817A1 (en) 2022-03-24 2023-09-28 Gilead Sciences, Inc. Combination therapy for treating trop-2 expressing cancers
TW202345901A (zh) 2022-04-05 2023-12-01 美商基利科學股份有限公司 用於治療結腸直腸癌之組合療法
TW202400138A (zh) 2022-04-21 2024-01-01 美商基利科學股份有限公司 Ｋｒａｓ ｇ１２ｄ調節化合物
WO2024005423A1 (ko) * 2022-06-29 2024-01-04 고려대학교 산학협력단 인간 FCγRS 결합력이 제거된 당화 FC 변이체들
WO2024006929A1 (en) 2022-07-01 2024-01-04 Gilead Sciences, Inc. Cd73 compounds
US20240010714A1 (en) * 2022-07-10 2024-01-11 Mbrace Therapeutics, Inc. Cell-free methods of recombinant antibody production
WO2024015741A1 (en) 2022-07-12 2024-01-18 Gilead Sciences, Inc. Hiv immunogenic polypeptides and vaccines and uses thereof
US20240091351A1 (en) 2022-09-21 2024-03-21 Gilead Sciences, Inc. FOCAL IONIZING RADIATION AND CD47/SIRPa DISRUPTION ANTICANCER COMBINATION THERAPY

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6005079A (en) 1992-08-21 1999-12-21 Vrije Universiteit Brussels Immunoglobulins devoid of light chains
PT1498427E (pt) 1992-08-21 2010-03-22 Univ Bruxelles Imunoglobulinas desprovidas de cadeias leves
US6838254B1 (en) 1993-04-29 2005-01-04 Conopco, Inc. Production of antibodies or (functionalized) fragments thereof derived from heavy chain immunoglobulins of camelidae
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
DE60042789D1 (de) 1999-11-29 2009-10-01 Bac Ip B V Immobilisierte antigenbindende moleküle aus einer domäne
AU2002368077B2 (en) 2001-07-12 2010-03-04 Jefferson Foote Super humanized antibodies
DE102007001370A1 (de) * 2007-01-09 2008-07-10 Curevac Gmbh RNA-kodierte Antikörper
US7744874B2 (en) * 2007-03-20 2010-06-29 Eli Lilly And Company Anti-sclerostin antibodies
EP2111869A1 (en) 2008-04-23 2009-10-28 Stichting Sanquin Bloedvoorziening Compositions and methods to enhance the immune system
WO2011004847A1 (ja) * 2009-07-07 2011-01-13 一般財団法人化学及血清療法研究所 新規ヒト化抗ヒトα９インテグリン抗体
PL2477648T3 (pl) 2009-09-15 2022-11-07 The Board Of Trustees Of The Leland Stanford Junior University Synergistyczna terapia anty-cd47 dla nowotworów hematologicznych
JP2014519338A (ja) * 2011-06-16 2014-08-14 ノバルティス アーゲー 治療薬として使用される可溶性タンパク質
CN104136037B (zh) * 2012-01-17 2018-02-23 小利兰·斯坦福大学托管委员会 高亲和力SIRP‑α试剂
US20140140989A1 (en) 2012-02-06 2014-05-22 Inhibrx Llc Non-Platelet Depleting and Non-Red Blood Cell Depleting CD47 Antibodies and Methods of Use Thereof
KR102100388B1 (ko) * 2012-02-06 2020-04-13 인히브릭스, 인크. Cd47 항체 및 그 사용 방법
JP2016507555A (ja) * 2013-02-06 2016-03-10 インヒブルクス エルピー 血小板非減少性かつ赤血球非減少性ｃｄ４７抗体及びその使用方法
HUE059565T2 (hu) * 2013-04-19 2022-11-28 Sutro Biopharma Inc Biológiailag aktív fehérjék expressziója bakteriális sejtmentes szintézisrendszerben, emelkedett exogén chaperonszintû sejtextraktumok segítségével
US10870699B2 (en) 2014-12-30 2020-12-22 Celgene Corporation Anti-CD47 antibodies and uses thereof
RU2748401C2 (ru) 2015-09-18 2021-05-25 Арч Онколоджи, Инк. Терапевтические антитела к CD47
NZ741324A (en) 2015-09-21 2021-09-24 Erasmus Univ Medical Center Anti-cd47 antibodies and methods of use

Also Published As

Publication number Publication date
US10870699B2 (en) 2020-12-22
CL2017001736A1 (es) 2018-03-16
JP6850255B2 (ja) 2021-03-31
US20170369572A1 (en) 2017-12-28
EA037654B1 (ru) 2021-04-27
US20210054070A1 (en) 2021-02-25
BR112017014258A2 (pt) 2018-03-06
US11787860B2 (en) 2023-10-17
WO2016109415A1 (en) 2016-07-07
CA2972604A1 (en) 2016-07-07
EA201791485A1 (ru) 2018-02-28
CN107530421A (zh) 2018-01-02
MX2017008819A (es) 2018-03-14
CO2017007673A2 (es) 2018-01-05
JP2018506964A (ja) 2018-03-15
ZA201704467B (en) 2019-09-25
SG11201705310TA (en) 2017-07-28
JP2021048858A (ja) 2021-04-01
CN107530421B (zh) 2021-07-20
HK1245154A1 (zh) 2018-08-24
EP3240569A1 (en) 2017-11-08
KR20170100652A (ko) 2017-09-04
AU2015374301A1 (en) 2017-07-20
ECSP17041865A (es) 2017-08-31
KR102489471B1 (ko) 2023-01-18
EP3240569A4 (en) 2018-05-30
CA2972604C (en) 2023-07-04
AU2015374301B2 (en) 2021-02-11

Similar Documents

Publication Publication Date Title
HK1245154A1 (zh) 抗cd47抗體及其用途
HK1255067A1 (zh) 抗c10orf54抗體及其用途
HK1243440A1 (zh) 抗白細胞介素-33抗體及其用途
HK1254861A1 (zh) 抗lag3抗體及其用途
HK1252615A1 (zh) Il-8-結合抗體及其應用
HK1249911A1 (zh) 抗muc16抗體及其應用
HK1250238A1 (zh) 抗angptl8抗體及其用途
HK1243940A1 (zh) 抗原肌肉生長抑制素/潛在肌肉生長抑制素的抗體及其用途
IL304772A (en) Antibodies, uses and methods
ZA201605894B (en) Anti-egfrviii antibodies and uses thereof
GB201403875D0 (en) Novel antibodies and uses thereof
GB201413913D0 (en) Novel antibodies and uses thereof
IL247315B (en) Anti-acth antibodies and their uses
ZA201701663B (en) Anti-il-25 antibodies and uses thereof
GB201503387D0 (en) Anti-carbapenem antibodies and uses thereof
HK1254240A1 (zh) 抗羥腐胺賴氨酸抗體及其用途